MIAMI -- Janet Woodcock, director of FDA's Center for Drug Evaluation and Research (CDER), announced Wednesday (Feb. 11) that the agency is planning to “radically change” its approach to quality enforcement with regards to generic and brand drug manufacturers in order to foster a culture of quality within the industry. Speaking at the Generic Pharmaceutical Association's (GPhA) annual conference in Miami, Woodcock said rather than just issuing citations for quality infractions FDA will give companies quality “report cards” following inspections,...
You've followed a link to an article or document on InsideHealthPolicy.com.
There are two ways you can access this content.
Subscriber Login
If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:
Take A Trial Subscription
If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.
Sign up for a trial subscription.